Caryn Lerman

Distinguished Professor of Psychiatry and the Behavioral Sciences and Psychology

H. Leslie Hoffman and Elaine S. Hoffman Chair in Cancer Research

Director USC Norris Comprehensive Cancer Center

Associate Dean for Cancer Programs

Image of Caryn Lerman
Is this your profile? Click to edit

Overview

Dr. Caryn Lerman is the Director of the USC Norris Comprehensive Cancer Center, Associate Dean for Cancer Programs, and the H. Leslie and Elaine S. Hoffman Cancer Research Chair at the Keck School of Medicine of USC. She is recognized for her cancer prevention research that bridges the fields of neuroscience, genomics, pharmacology, and population science. A major unifying focus of her research is biology-driven science to reduce cancer risk behaviors. This work has spawned novel lines of investigation, including: the behavioral epidemiology of cancer genetic susceptibility testing; pharmacogenomic approaches to tobacco dependence leading to the first prospective stratified pharmacogenomic trial in this area; and neuroscience-based interventions to reduce tobacco dependence. Her current research focus is on the therapeutic potential of psilocybin and other psychedelic therapies.

An elected member of the National Academy of Medicine, Dr. Lerman has served as a member of the NCI Board of Scientific Advisors, the National Human Genome Research Advisory Council, and the National Institutes on Drug Abuse Advisory Council. She is the current Vice President/President-Elect of the Association of American Cancer Institutes and a past president of the Society for Research on Nicotine and Tobacco. Additional awards and honors include the American Cancer Society Cancer Control Award, the American Society of Preventive Oncology Joseph Cullen Award, the Alton Ochsner Award Relating Smoking and Health, the NIH Matilda White Riley Award, and the Los Angeles Business Journal award for Women Leaders in Healthcare.

Prior to her appointment as Director of the USC Norris Comprehensive Cancer Center, Associate Dean for Cancer Programs, and H. Leslie and Elaine S. Hoffman Cancer Research Chair at USC’s Keck School of Medicine, Dr. Lerman served as Senior Deputy Director of the Abramson Cancer Center and Vice Dean for Strategic Initiatives in the Perelman School of Medicine at the University of Pennsylvania.

Awards

  • Title(s)Distinguished Professor of Psychiatry and the Behavioral Sciences and PsychologySchoolKeck School of Medicine of UscPhone+1 323 865 0816vCardDownload vCard: Download vCard, Title(s)Distinguished Professor of Psychiatry and the Behavioral Sciences and PsychologySchoolKeck School of Medicine of UscPhone+1 323 865 0816vCardDownload vCard Title(s)Distinguished Professor of Psychiatry and the Behavioral Sciences and PsychologySchoolKeck School of Medicine of UscPhone+1 323 865 0816vCardDownload vCard +1 323 865 0816
  • Title(s)Distinguished Professor of Psychiatry and the Behavioral Sciences and PsychologySchoolKeck School of Medicine of UscPhone+1 323 865 0816vCardDownload vCard: Download vCard, Title(s)Distinguished Professor of Psychiatry and the Behavioral Sciences and PsychologySchoolKeck School of Medicine of UscPhone+1 323 865 0816vCardDownload vCard +1 323 865 0816

Research Funding

  • USC Tobacco Center of Regulatory Science
    NCI · Sep 1, 2023 – Aug 31, 2028 · Role: Co-Investigator
  • Neural basis of smoking relapse
    NIH · R01DA041402 · Apr 1, 2016 – Jan 31, 2021 · Role: Principal Investigator
  • Neuroscience-based Interventions for Cancer Risk Behavior Change
    NIH · R35CA197461 · Aug 1, 2015 – Jul 31, 2022 · Role: Principal Investigator
  • USC Tobacco Center of Regulatory Science
    NIH · U54CA180905 · Sep 19, 2013 – Aug 31, 2028 · Role: Co-Principal Investigator
  • UPENN TCORS: Tobacco Product Messaging in a Complex Communication Environment
    NIH · P50CA179546 · Sep 18, 2013 – Aug 31, 2019 · Role: Co-Principal Investigator
  • Retraining Neurocognitive Mechanisms of Cancer Risk Behavior (PQ4)
    NIH · R01CA170297 · Sep 1, 2012 – Jun 30, 2018 · Role: Principal Investigator
  • Cognitive Training for Nicotine Dependence
    NIH · R01DA030819 · Sep 30, 2010 – Jun 30, 2016 · Role: Principal Investigator
  • Abramson Cancer Center Support Grant
    NIH · P30CA147859 · Sep 30, 2009 – Sep 29, 2012 · Role: Principal Investigator
  • Functional Characterization of OPRM1 A118G in Nicotine Dependence
    NIH · R21DA027066 · Sep 30, 2009 – Aug 31, 2011 · Role: Co-Principal Investigator
  • Nicotine Abstinence-Induced Cognitive Alterations by COMT Genotype
    NIH · R03DA027438 · Sep 15, 2009 – Aug 31, 2012 · Role: Principal Investigator
  • Center for Interdisciplinary Research on Nicotine Addiction (CIRNA)
    NIH · P50CA143187 · Aug 1, 2009 – Jul 31, 2015 · Role: Principal Investigator
  • Neural Substrates of Cognitive Deficits in Nicotine Withdrawal
    NIH · R01DA026849 · Aug 1, 2009 – May 31, 2013 · Role: Principal Investigator
  • Pharmacogenetics of Nicotine Addiction Treatment
    NIH · U01DA020830 · Sep 15, 2005 – Jun 30, 2016 · Role: Principal Investigator
  • Pharmacogenetic Investigation of Naltrexone
    NIH · R01DA017555 · Sep 30, 2003 – Jun 30, 2009 · Role: Principal Investigator
  • Transdisciplinary Tobacco Use Research Centers
    NIH · P50CA084718 · Sep 30, 1999 – Sep 29, 2009 · Role: Principal Investigator
  • CANCER GENETICS NETWORK
    NIH · U24CA078146 · Aug 1, 1998 – Sep 30, 2007 · Role: Co-Principal Investigator
  • Decisions &Outcomes of BRCA1/2 Test for Breast Patients
    NIH · R01CA074861 · Aug 1, 1997 – Jun 30, 2010 · Role: Co-Principal Investigator
  • University of Southern California Cancer Center Support Grant
    NCI · Dec 1, 1996 – Nov 30, 2026 · Role: Principal Investigator
  • COMPARING MODELS OF COUNSELING FOR BRCA1/2 TESTING
    NIH · R01HG001846 · Sep 30, 1994 – Aug 31, 2002 · Role: Co-Principal Investigator
  • COMPARING MODELS OF PRETEST EDUCATION FOR BRCA1 TESTING
    NIH · R01MH054435 · Sep 30, 1994 – Aug 31, 1998 · Role: Principal Investigator
  • COUNSELING WOMEN AT RISK FOR BREAST CANCER
    NIH · R01CA063605 · Sep 30, 1993 – Jul 31, 1998 · Role: Principal Investigator
  • BIOBEHAVIORAL LUNG CANCER PREVENTION PROGRAM
    NIH · R01CA063562 · Sep 10, 1993 – May 31, 2004 · Role: Principal Investigator
  • IMPROVING ADHERENCE IN WOMEN AT RISK FOR BREAST CANCER
    NIH · R01CA057767 · Sep 30, 1992 – Feb 28, 1998 · Role: Principal Investigator
  • PREVENTIVE ONCOLOGY ACADEMIC AWARD
    NIH · K07CA001604 · Jul 1, 1991 – Jun 30, 1996 · Role: Principal Investigator
  • University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
    NIH · P30CA014089 · Apr 1, 1980 – Nov 30, 2026 · Role: Co-Principal Investigator
  • Abramson Cancer Center Support Grant
    NIH · P30CA016520 · Nov 30, 2027 · Role: Co-Principal Investigator

Publications

  • Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk. Breast Cancer Res Treat. 2026 Jul 10; 218(1).. View in PubMed
  • Faster CYP2A6 increases COPD and lung cancer risk by increasing smoking quantity: a mediated mendelian randomization and observational mediation study. Respir Res. 2026 Jun 01.. View in PubMed
  • Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study. Cancer Epidemiol Biomarkers Prev. 2025 Sep 02; 34(9):1618-1626.. View in PubMed
  • A multi-site study examining the tobacco withdrawal trajectory in people with tobacco and cannabis co-use. Drug Alcohol Depend. 2025 Sep 01; 274:112778.. View in PubMed
  • MammaTrace – a cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer patients. medRxiv. 2025 May 21.. View in PubMed
  • Sex dependent genetic architecture of biochemically verified tobacco use. Psychiatry Res. 2025 Jun; 348:116465.. View in PubMed
  • Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality. Cancer Res. 2024 12 02; 84(23):3924-3935.. View in PubMed
  • A structural MRI marker predicts individual differences in impulsivity and classifies patients with behavioral-variant frontotemporal dementia from matched controls. bioRxiv. 2024 Sep 16.. View in PubMed
  • Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers. Mol Psychiatry. 2025 Mar; 30(3):943-953.. View in PubMed
  • Multivariate analysis of multimodal brain structure predicts individual differences in risk and intertemporal preference. bioRxiv. 2024 Jul 08.. View in PubMed